HealthEquity Inc (HQY) Shares Oversold with RSI at 28.8
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: NASDAQ.COM
- Oversold Signal: HealthEquity Inc (HQY) shares dropped to $84.505 on Monday, with an RSI of 28.8, indicating that the recent heavy selling may be exhausting, potentially providing entry points for bullish investors.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 67.4, HQY's 28.8 RSI suggests relative weakness, which may attract investors looking for undervalued opportunities.
- Historical Performance: HQY's 52-week low is $74.07 and high is $116.65, with the current trading price of $84.55 reflecting its performance within this range, prompting a reassessment by investors.
- Investor Sentiment: While the stock is currently oversold, investors should cautiously evaluate market trends to avoid making impulsive decisions in an uncertain market environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HQY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HQY
Wall Street analysts forecast HQY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HQY is 117.09 USD with a low forecast of 89.00 USD and a high forecast of 129.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
9 Buy
1 Hold
1 Sell
Moderate Buy
Current: 83.570
Low
89.00
Averages
117.09
High
129.00
Current: 83.570
Low
89.00
Averages
117.09
High
129.00
About HQY
HealthEquity, Inc. is engaged in providing technology-enabled services that enables consumers to make healthcare saving and spending decisions. The Company uses its technology to manage consumer tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and to administer Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It provides consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice. It offers an investment platform and access to an online-only automated investment advisory service to all of its members whose account balances exceed a stated threshold. It administers pre-tax commuter benefit programs through which employers are permitted to provide employees with commuter benefits including qualified transit and parking.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
White House Unveils Healthcare Plan to Slash Drug Prices and Transform Industry Dynamics
- Drug Price Reform: The White House's unveiling of 'The Great Healthcare Plan' on January 15, 2026, aims to significantly reduce prescription drug prices through 'Most-Favored-Nation' pricing agreements, alleviating consumer burdens and reshaping the pharmaceutical market landscape.
- Subsidy Shift: By redirecting insurance subsidies directly to consumers instead of insurers, the plan is expected to lower insurance costs and enhance consumer choice, thereby impacting the revenue models of traditional insurance companies.
- Retail Pharmacy Gains: The proposal to allow more prescription drugs to be sold over-the-counter will directly boost sales for retail pharmacies like Walmart, increasing foot traffic and enhancing the profitability of their clinic operations.
- Portfolio Reevaluation: Investors are advised to reassess their ETF portfolios, prioritizing companies that benefit from the new policies, such as HealthEquity and the iShares U.S. Pharmaceuticals ETF, while avoiding middlemen companies facing regulatory pressures.
Continue Reading
HealthEquity Inc (HQY) Shares Oversold with RSI at 28.8
- Oversold Signal: HealthEquity Inc (HQY) shares dropped to $84.505 on Monday, with an RSI of 28.8, indicating that the recent heavy selling may be exhausting, potentially providing entry points for bullish investors.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 67.4, HQY's 28.8 RSI suggests relative weakness, which may attract investors looking for undervalued opportunities.
- Historical Performance: HQY's 52-week low is $74.07 and high is $116.65, with the current trading price of $84.55 reflecting its performance within this range, prompting a reassessment by investors.
- Investor Sentiment: While the stock is currently oversold, investors should cautiously evaluate market trends to avoid making impulsive decisions in an uncertain market environment.
Continue Reading